Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

Non Small Cell Lung Cancer Clinical Trial

— WU-KONG15  

Official title:

DZD9008 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutations: Cohort Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05559645
• Other study ID #: DZ2021E0006
• Status: Recruiting
• Phase: N/A
• Start date: November 18, 2021
• Est. completion date: June 30, 2026

Study information

• Verified date: May 2024
• Source: Peking Union Medical College Hospital
• Contact: Yan Xu, Dr.
• Phone: 010-69155039
• Email: maraxu[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single center cohort study to access the anti-tumor efficacy, safety and tolerability of DZD9008 in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations and EGFR uncommon mutations who have progressed following standard TKI therapy, and in treatment naive patients with NSCLC harboring EGFR Exon20 insertion mutation and EGFR sensitizing mutations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: June 30, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. To provide a signed and dated, written informed consent.

2. Aged = 18 years old

3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC with documented EGFR mutations from a local laboratory

4. ECOG performance status 0-1.

5. Predicted life expectancy = 12 weeks

6. Patient must have measurable disease according to RECIST 1.1.

7. Patient who has progressed or intolerant to standard therapy (except treatment naïve patients in Cohort 4 and Cohort 7: with EGFR Exon20ins; and in Cohort 5 with EGFR sensitizing mutation).

8. Patients with brain metastasis (BM) can be enrolled under the condition that BM is stable, neurologically asymptomatic and does not require corticosteroid treatment.

9. Adequate organ system function.

• Absolute neutrophil count (ANC) = 1.5 x 10^9/L

• Platelets = 100 x 10^9/L

• Hemoglobin = 9 g/dL

• Total bilirubin = 1.5 x ULN if no liver metastases or = 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN if no liver metastases or = 5 x ULN with liver metastases

• Creatinine = 1.5 x ULN, concurrent with calculated or measured creatinine clearance = 50 mL/min as calculated by the Cockcroft-Gault method or = 50 mL/min in 24 hours

• International normalized ratio (INR) = 1.5 x ULN and activated partial thromboplastin time (APTT) = 1.5 x ULN;

• Serum amylase = 1.5 x ULN and serum lipase = 1.5 x ULN

Exclusion criteria:

1. Known history of bleeding diathesis.

2. Prior malignancy within 2 years requires active treatment.

3. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of first administration.

4. History of stroke or intracranial haemorrhage within 6 months before the first administration.

5. Spinal cord compression or leptomeningeal metastasis.

6. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).

7. Any of the following cardiac criteria:

• Mean resting corrected QT interval (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs);

• Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec.

• Any factors that increase the risk of QTcF prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.

• Prior history of atrial fibrillation within 6 months of first administration of DZD9008, except prior drug treatment related and recovered.

8. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.

9. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of DZD9008.

10. History of hypersensitivity to active or inactive excipients of DZD9008 or drugs with a similar chemical structure or class to DZD9008.

11. Women who are pregnant or breast feeding.

12. Involvement in the planning and conduct of the study.

13. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• DZD9008
Daily dosing of DZD9008 200mg
• DZD9008
Daily dosing of DZD9008 300mg

Locations

Country	Name	City	State
China	Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital	Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Disease Control rate (DCR)	To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator	through study completion, an average of 1 year
Other	Objective Response Rate (ORR)	To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator	through study completion, an average of 1 year
Other	Overall survival (OS)	To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator	through study completion, an average of 1 year
Other	Number of participants with adverse events (AEs) according to CTCAE 5.0	To assess safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC	From first dose until 28 days after the last dose
Other	Number of participants with clinically significant laboratory assessment abnormalities	To assess safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC	From first dose until 30 days after the last dose
Other	Number of participants with clinically significant abnormal vital signs	To assess safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC	From first dose until 30 days after the last dose
Other	Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities	To assess safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC	From first dose until 30 days after the last dose
Primary	Progression-free survival (PFS)	To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator	through study completion, an average of 1 year
Secondary	Duration of Response (DoR)	To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator	through study completion, an average of 1 year